.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
UBS
Boehringer Ingelheim
Chinese Patent Office
Mallinckrodt
Medtronic
Novartis
Express Scripts
Farmers Insurance
Deloitte

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,287,847

« Back to Dashboard

Which drugs does patent 8,287,847 protect, and when does it expire?


Patent 8,287,847 protects VELTASSA and is included in one NDA.

This patent has eighty-three patent family members in sixteen countries.

Summary for Patent: 8,287,847

Title:Ion binding polymers and uses thereof
Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.
Inventor(s): Charmot; Dominique (Campbell, CA), Chang; Han-Ting (Livermore, CA), Liu; Mingjun (Campbell, CA), Klaerner; Gerrit (San Jose, CA)
Assignee: Relypsa, Inc. (Santa Clara, CA)
Application Number:12/055,765
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Relypsa IncVELTASSApatiromer sorbitex calciumPOWDER;ORAL205739-001Oct 21, 2015RXYesNo► Subscribe► Subscribe► SubscribeTREATMENT OF HYPERKALEMIA
Relypsa IncVELTASSApatiromer sorbitex calciumPOWDER;ORAL205739-002Oct 21, 2015RXYesNo► Subscribe► Subscribe► SubscribeTREATMENT OF HYPERKALEMIA
Relypsa IncVELTASSApatiromer sorbitex calciumPOWDER;ORAL205739-003Oct 21, 2015RXYesYes► Subscribe► Subscribe► SubscribeTREATMENT OF HYPERKALEMIA
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,287,847

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,192,758Ion binding compositions► Subscribe
8,889,115Ion binding polymers and uses thereof► Subscribe
8,445,014Ion binding compositions► Subscribe
7,429,394Ion binding compositions► Subscribe
8,216,560Ion binding polymers and uses thereof► Subscribe
8,475,780Ion binding polymers and uses thereof► Subscribe
8,282,913Ion binding polymers and uses thereof► Subscribe
8,147,873Methods and compositions for treatment of ion imbalances► Subscribe
7,776,319Methods and compositions for treatment of ion imbalances► Subscribe
8,282,960Ion binding compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,287,847

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal2269589► Subscribe
Portugal2184059► Subscribe
MexicoPA06011270► Subscribe
South Korea20130086262► Subscribe
South Korea101399238► Subscribe
South Korea20140003661► Subscribe
South Korea101362509► Subscribe
South Korea20120130255► Subscribe
South Korea101269766► Subscribe
South Korea20120060920► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Fuji
Argus Health
Teva
Queensland Health
Mallinckrodt
Moodys
McKesson
Boehringer Ingelheim
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot